Summary:
In super-obese patients with type 2 diabetes mellitus (T2DM), weekly polyethylene glycol loxenatide (PEG-Loxe) treatment significantly reduced body weight and improved metabolic outcomes compared to placebo, with greater effects observed at the 400 μg dose versus 300 μg, though it was associated with higher rates of gastrointestinal side effects.
| PICO | Description |
|---|---|
| Population | Adults with super-obesity and type 2 diabetes mellitus enrolled in a single-center randomized controlled trial. |
| Intervention | Weekly subcutaneous injections of polyethylene glycol loxenatide (PEG-Loxe) at 300 μg or 400 μg for 24 weeks. |
| Comparison | Placebo group receiving weekly injections over the same time frame (24 weeks). |
| Outcome | At 24 weeks, significant weight reduction observed: -16.34 kg (300 μg), -21.14 kg (400 μg) vs -6.75 kg (placebo); HbA1c decreased by 1.02% (300 μg), 1.34% (400 μg) vs 0.50% (placebo); waist circumference and HDL cholesterol improved. Higher incidence of GI adverse events in treatment groups (36.11% for 400 μg, 25.00% for 300 μg) versus placebo (11.43%). |
Source: Zenglin Liu, et al. “Effect of polyethylene glycol loxenatide on weight loss in super-obese patients with type 2 diabetes: a randomized controlled trial.” Read article here.
